Ann Rheum Dis 2001;60:1117-1122 ( December )

Extended report

Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale Á J Geirsson, F A Wollheim, A Åkesson

Department of Rheumatology, University Hospital, Lund, Sweden

Correspondence to: Dr Á J Geirsson, Department of Medicine, University Hospital, Landspítalinn, 101 Reykjavík, Iceland arnijon{at}rsp.is

Accepted for publication 14 May 2001

OBJECTIVETo assess organ involvement according to a modified Medsger severity scale and its relation to outcome and prognosis in patients with systemic sclerosis.
METHODSOne hundred consecutive patients observed in Lund with systemic sclerosis were followed up for a period of 14 years. The mean follow up time was 7.7 years. Initial assessment and an annual evaluation was performed for each patient, with a mean visit frequency of 5.6 per patient.
RESULTSAge at referral, high total skin score, truncal skin involvement, low vital capacity, low static lung compliance, low Cr-EDTA clearance, and ECG abnormalities at the initial assessment predict poor outcome. A severity scoring system for five organ systems indicates a slow progression of organ dysfunction after recruitment into the study. The female: male ratio was 2:1, the mean age at onset of symptoms was 42.3 (range 3-82), and the mean age at recruitment was 47.2 years (range 17-82). Thirty patients died during the follow up period at the mean age of 61.3 years (range 33-85). The causes of death were directly related to systemic sclerosis in at least 10 patients, infections in six, cancers in nine, and other causes in four patients. The standardised mortality ratio was 3.5 and 3.7 for men and women, respectively.
CONCLUSIONA high severity score for function of vital organs was shown to predict shortened survival. In this study a severity score based on simple clinical assessment variables was able to predict poor outcome from extensive skin changes, ECG changes, and compromised lung and renal function. Organ dysfunction mainly became manifest during the first five years of the disease, whereafter organ function remained largely stable.

---

© 2001 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Doran, J. P., Veale, D. J. (2008). Biomarkers in systemic sclerosis. Rheumatology (Oxford) 47: v36-v38 [Abstract] [Full Text]  
• Goldin, J. G., Lynch, D. A., Strollo, D. C., Suh, R. D., Schraufnagel, D. E., Clements, P. J., Elashoff, R. M., Furst, D. E., Vasunilashorn, S., McNitt-Gray, M. F., Brown, M. S., Roth, M. D., Tashkin, D. P., for the Scleroderma Lung Study Research Group, (2008). High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease. Chest 134: 358-367 [Abstract] [Full Text]  
• Baron, M, Sutton, E, Hudson, M, Thombs, B, Markland, J, Pope, J, Robinson, D, Jones, N, Docherty, P, Abu-Hakima, M, LeClercq, S, Smith, D, Mathieu, J-P (2008). The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 67: 644-650 [Abstract] [Full Text]  
• Strange, C., Bolster, M. B., Roth, M. D., Silver, R. M., Theodore, A., Goldin, J., Clements, P., Chung, J., Elashoff, R. M., Suh, R., Smith, E. A., Furst, D. E., Tashkin, D. P., the Scleroderma Lung Study Research Group, (2008). Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease. Am. J. Respir. Crit. Care Med. 177: 91-98 [Abstract] [Full Text]  
• Czirjak, L, Kumanovics, G, Varju, C, Nagy, Z, Pakozdi, A, Szekanecz, Z, Szucs, G (2008). Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67: 59-63 [Abstract] [Full Text]  
• Vonk, M C, Marjanovic, Z, van den Hoogen, F H J, Zohar, S, Schattenberg, A V M B, Fibbe, W E, Larghero, J, Gluckman, E, Preijers, F W M B, van Dijk, A P J, Bax, J J, Roblot, P, van Riel, P L C M, van Laar, J M, Farge, D (2008). Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67: 98-104 [Abstract] [Full Text]  
• Serednicka, K., Smyth, A. E., Black, C. M., Denton, C. P. (2007). Using a self-reported functional score to assess disease progression in systemic sclerosis. Rheumatology (Oxford) 46: 1107-1110 [Abstract] [Full Text]  
• Rigamonti, C, Shand, L M, Feudjo, M, Bunn, C C, Black, C M, Denton, C P, Burroughs, A K (2006). Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55: 388-394 [Abstract] [Full Text]